In Reply

Debra L. Richardson; Robert L. Coleman; Michael W. Sill

doi:10.1001/jamaoncol.2018.1712

In Reply

Debra L. Richardson, Robert L. Coleman, Michael W. Sill

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1299
Number of pages	1
Journal	JAMA Oncology
Volume	4
Issue number	9
DOIs	https://doi.org/10.1001/jamaoncol.2018.1712
State	Published - Sep 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2018.1712

Cite this

@article{46efe4edcd1f42ec8043511d0bf85adc,

title = "In Reply",

author = "Richardson, {Debra L.} and Coleman, {Robert L.} and Sill, {Michael W.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.",

year = "2018",

month = sep,

doi = "10.1001/jamaoncol.2018.1712",

language = "English (US)",

volume = "4",

pages = "1299",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - In Reply

AU - Richardson, Debra L.

AU - Coleman, Robert L.

AU - Sill, Michael W.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.

PY - 2018/9

Y1 - 2018/9

UR - http://www.scopus.com/inward/record.url?scp=85053429329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053429329&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.1712

DO - 10.1001/jamaoncol.2018.1712

M3 - Letter

C2 - 29978183

AN - SCOPUS:85053429329

SN - 2374-2437

VL - 4

SP - 1299

JO - JAMA Oncology

JF - JAMA Oncology

IS - 9

ER -

In Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this